You are viewing the site in preview mode

Skip to main content

Table 3 Co-morbidities in Hypopituitary patients

From: Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up

Comorbidities   Age (years) P- value
Total
(n = 35)
70–74 (%)
(n = 16)
75–79 (%)
(n = 12)
80–99 (%)
(n = 7)
 
Hypertensiona (%) 85.7 93.8 83.3 71.4 0.35
Diabetesb (%) 37.1 43.8 33.3 28.5 0.74
HDL < 40 men/ HDL < 50 women 53.1 64.3 50 33.3 0.42
Hypertrigliceridemia > 150 mg/dL (%) 51.5 57.1 58.3 28.5 0.39
Hypopituitarism (%)
 GH deficiency 65.71 56.2 66.7 85.7 0.39
 Hypogonadism 88.6 87.5 83.3 100 0.53
 Hypothyroidism 82.9 87.5 83.3 71.4 0.64
 Adrenal Insufficiency 25.7 12.5 33.3 42.9 0.23
Multiple Pituitary Hormone Deficiencies (MPHD)      0.52
 2 axes 45.7 50 41.7 42.9  
 3 axes 28.6 37.5 25 14.3  
 4 axes 20 6.2 25 42.9  
  1. aMost patients treated by enalapril and valsartan
  2. b Patients treated by diet, metformin and/or glibenclamide